World journal of clinical oncology最新文献

{"title":"Mutational profile of a Saudi patient with Familial adenomatous polyposis that progressed to colon cancer: A case report.","authors":"Ghada E Esheba, Hala Fm Kamel, Heba Mk Youssef, Hatoon Fm Badawood, Abdullah A Alshamrani, Rehab J Alharbi, Rami Nassir","doi":"10.5306/wjco.v16.i8.108865","DOIUrl":"10.5306/wjco.v16.i8.108865","url":null,"abstract":"<p><strong>Background: </strong>Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome that results from a germline mutation in the adenomatous polyposis coli gene. It is characterized by the early development of hundreds of adenomas in the colon during the second decade of life. If prophylactic colectomy is not performed, most patients eventually develop colorectal cancer (CRC).</p><p><strong>Case summary: </strong>We present the mutational profile of a case of FAP that progressed to CRC. A 45-year-old Saudi man presented with intestinal obstruction and underwent a total colectomy. The colon showed hundreds of polyps and two infiltrative ulcerative lesions, which proved to be adenocarcinoma according to histopathology. We performed next-generation sequencing and found mutations in the <i>TP53, NRAS, EGFR PDGFR, MET, KIT, ERBB2,</i> and <i>GUSP</i> genes.</p><p><strong>Conclusion: </strong>To the best of our knowledge, this case report is the first to sheds the light on the mutation profile of FAP that progressed to CRC in Saudi Arabia.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"108865"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early diagnosis of depressive symptoms as part of the comprehensive management of breast cancer patients.","authors":"Macarena Teja, Abrahams Ocanto, Felipe Couñago","doi":"10.5306/wjco.v16.i8.106627","DOIUrl":"10.5306/wjco.v16.i8.106627","url":null,"abstract":"<p><p>Breast cancer is the most common cancer in women worldwide. A high percentage of these patients may have depressive symptoms and an early detection is crucial as part of a comprehensive management of the disease. Mao <i>et al</i> recently conducted a study constructing a depression risk predictive model in young and middle-aged breast cancer patients. Four questionnaires (a general one, Patient Health Questionnaire-9, Perceived Social Support From Family Scale and International Physical Activity Questionnaire) and the Visual Analogue Scale were used to examine the correlation between different variables and depressive symptoms. The constructed predictive model showed strong predictive capability with an area under the receiver operating characteristic curve of 0.852 and high sensitivity and specificity values. However, the screening depression tools and questionnaires to assess social support or physical activity are not originally designed for oncological patients and further investigation to corroborate their applicability in this context is relevant. The cross-sectional design of the study prevents establishing clear causal relationships between the identified risk factors and depression. Besides, the study includes only a sample of Chinese patients and the applicability in a different sociocultural context is uncertain. Further investigation is crucial to corroborate the results in larger samples and different contexts.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"106627"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HOXC6-TIMELESS axis: Unveiling novel therapeutic strategies in bladder cancer.","authors":"Meng-Meng Shi, Ming-Yue Guan, Shi Li, Jie-Yu Guo, Xing-Zhen Chen, Jing-Feng Tang, Ce-Fan Zhou","doi":"10.5306/wjco.v16.i7.108071","DOIUrl":"10.5306/wjco.v16.i7.108071","url":null,"abstract":"<p><p>Bladder cancer (BLCA) is a highly invasive malignancy with limited targeted therapies. Lu <i>et al</i> reveal the oncogenic role of HOXC6 in BLCA by showing its elevated mRNA and protein levels in cancerous tissues. Silencing HOXC6 significantly inhibits BLCA cell proliferation, migration and invasion, induces apoptosis and arrests the cell cycle at G0/G1. In addition, HOXC6 also regulates pathways related to chemical carcinogenesis and reactive oxygen species, with a strong association with the target gene TIMELESS, supported by binding signals in its promoter region. Here, we discuss the role of HOXC6 as a potential biomarker and therapeutic target, contributing to a deeper understanding of the HOXC6-TIMELESS axis and its implications for advancing BLCA research and therapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108071"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity as a risk factor for early-onset colorectal cancer: Evidence from a nationally representative database.","authors":"Omar Khattab, Mohamed Alharami, Frhaan Zahrawi, Ammar Hemaidan","doi":"10.5306/wjco.v16.i7.108220","DOIUrl":"10.5306/wjco.v16.i7.108220","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide with an alarming rise in early-onset CRC (eoCRC) over the past several decades. Unlike late-onset CRC, the drivers behind eoCRC remain less clear. While certain risk factors such as obesity and smoking have demonstrated a relatively strong association with eoCRC in the literature, some studies have challenged these associations, emphasizing the need for additional studies.</p><p><strong>Aim: </strong>To investigate the impact of various risk factors on eoCRC with a special focus on obesity.</p><p><strong>Methods: </strong>This cross-sectional study used de-identified data from the National Health and Nutrition Examination Survey (1999-2023), including 30321 United States adults aged 18 to 49 years. Participants with missing key variables were excluded. Standardized protocols were used to collect demographic, lifestyle, anthropometric [body mass index (BMI), body roundness index (BRI), waist circumference (WC)], and self-reported CRC data. Logistic regression and propensity score matching assessed associations between obesity-related parameters and eoCRC. Statistical analyses were performed in R and Stata, with <i>P</i> < 0.05 defined as significant.</p><p><strong>Results: </strong>Of 30321 participants, 48 received a diagnosis of eoCRC. Patients with eoCRC were older (mean age 39.96 years <i>vs</i> 34.36 years; <i>P</i> < 0.001) and had higher WC and BRI. None of the eoCRC patients were heavy drinkers (<i>P</i> = 0.006). Unadjusted models demonstrated significant associations of eoCRC with BRI quartiles, as well as BMI-defined obesity, WC, and smoking. In unadjusted models, BRI remained the strongest independent predictor; those in the highest BRI quartiles had over 10-fold greater odds of eoCRC. In fully adjusted models, BRI remained significant, but BMI- and waist-based obesity were not.</p><p><strong>Conclusion: </strong>BRI is a stronger predictor of eoCRC risk compared to other obesity indices and is a superior tool for identifying young individuals at higher risk of CRC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108220"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of propofol on gastrointestinal cancer outcomes: A review of cellular behavior, growth, and metastasis.","authors":"Funda Arun, Oguzhan Arun","doi":"10.5306/wjco.v16.i7.104727","DOIUrl":"10.5306/wjco.v16.i7.104727","url":null,"abstract":"<p><p>Cancer is one of the most important health problems that deeply affects all humanity and will have groundbreaking consequences in human history with its elimination. Gastrointestinal cancers, including colon and rectum, stomach, liver, pancreatic, and esophageal, account for 26% of the global cancer incidence and 35% of cancer-related deaths. Unfortunately, it is estimated that today's high incidence and mortality rates will increase by 58% and 73% by 2040, respectively. Although the treatment process includes novel options such as immunotherapy in addition to classical options with a multidisciplinary approach, surgical treatment under general anesthesia remains the leading option. Considering a long-lasting cancer process, it is quite surprising that a very short-term anesthetic administration can have various effects on cancer cell behavior. Various anesthetic approaches such as regional blocks used in pain management, the use of anesthetic adjuvants such as β-adrenoceptor antagonists, nonsteroidal anti-inflammatory drugs, and intravenous lidocaine, and the choice of anesthetic drugs seem to have potential effects on long-term cancer outcomes. Propofol is an intravenous anesthetic drug that is used for both induction and maintenance of general anesthesia. Many <i>in vitro</i> and clinical studies examining the effects of propofol comparatively with other anesthetic agents on tumor recurrence and metastasis revealed possible effects on tumor cell signaling, the immune response, and the modulation of the neuroendocrine stress response. However, the evidence from all these <i>in vitro</i> and clinical studies is different, complicated, and inconsistent. The general effects of propofol on the behavioral patterns, growth, and metastasis of gastrointestinal tumor cells, as well as the clinical features and consequences resulting from these effects, constitute the subject of this review.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"104727"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key players in the breast cancer microenvironment: From fibroblasts to immune cells.","authors":"Sacide Çakal, Buket Er Urgancı, Selda Şimşek","doi":"10.5306/wjco.v16.i7.107339","DOIUrl":"10.5306/wjco.v16.i7.107339","url":null,"abstract":"<p><p>Breast cancer is one of the most common malignancies worldwide and is a major cause of cancer-related mortality among women. Beyond tumor cells, the tumor microenvironment (TME) also plays an important role in cancer progression, therapy resistance, and metastasis. The TME is a complex ecosystem consisting of stromal and immune cells, extracellular matrix (ECM), and various signaling molecules that dynamically interact with tumor cells. Cancer-associated fibroblasts remodel the ECM and secrete growth factors that promote tumor growth and invasion. Immune cells, such as tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells, often contribute to an immunosuppressive environment that hinders anti-tumor immune responses. The ECM provides structural support and acts as a reservoir for signaling molecules that influence cancer cell behavior. These components evolve together with tumor cells, facilitating immune evasion, therapy resistance, and epithelial-to-mesenchymal transition, which promotes metastasis. Understanding these interactions is necessary to develop novel therapeutic strategies that target both tumor and microenvironmental components. This minireview highlights the key stromal and immune elements within the breast cancer microenvironment, discussing their individual and collective roles in tumor progression and clinical outcomes, while emphasizing emerging therapeutic approaches aiming to reprogram the TME to improve treatment efficacy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107339"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New advances in oral microbiology and tumor research.","authors":"Hong-Jun Liang, Xian-Yi Tan, Di Li, Cheng Lin, Suo-Yi Huang, Guo-Chao Nie, Xue-Feng Guo, Zheng-Bao Zhang, Xiao-Nian Zhu, Sheng-Kui Tan","doi":"10.5306/wjco.v16.i7.106981","DOIUrl":"10.5306/wjco.v16.i7.106981","url":null,"abstract":"<p><p>Cancer remains a major global health concern, with escalating incidence and mortality rates underscoring the urgent need for novel diagnostic and therapeutic strategies. Increasing evidence has identified the oral microbiota as a critical contributor to tumorigenesis, thereby expanding the understanding of cancer pathogenesis beyond conventional risk factors such as tobacco use and genetic predisposition. This review summarizes recent progress in elucidating the complex relationship between the oral microbiota and various malignancies, particularly oral squamous cell carcinoma, esophageal adenocarcinoma, and pancreatic ductal adenocarcinoma. Pathogenic bacteria, including <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i>, have been implicated in promoting tumor progression through mechanisms involving chronic inflammation, the production of metabolic toxins, and immune evasion. The dysbiosis of the oral microbiota, often driven by lifestyle factors such as poor diet, tobacco use, and alcohol consumption, further exacerbates these carcinogenic processes. Emerging therapeutic approaches including probiotics, oral microbiota transplantation, and CRISPR-based bacterial editing are under investigation for their potential to restore microbial homeostasis and suppress pathogenic species. Additionally, saliva-based microbial biomarkers have shown promise for non-invasive cancer screening. The integration of multi-omics technologies and artificial intelligence-driven platforms is further advancing the development of precision oncology. This review aims to consolidate fragmented findings concerning the oral microbiota-cancer axis and address existing gaps in mechanistic understanding. The review's significance lies in the translational potential of microbial research to clinical applications, offering opportunities to reduce the global cancer burden through early detection and microbiota-targeted therapies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"106981"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing cancer care: Bioprinting prostate cancer stem cells for targeted treatments.","authors":"Jaimina Gharia, Shriya Pimplaskar, Akhilesh Prajapati","doi":"10.5306/wjco.v16.i7.107007","DOIUrl":"10.5306/wjco.v16.i7.107007","url":null,"abstract":"<p><p>Prostate cancer (PCa), one of the leading causes of cancer-related mortality in men worldwide, presents significant challenges due to its heterogeneity and the presence of cancer stem cells (CSCs), which contribute to therapy resistance and metastasis. Advances in three-dimensional (3D) bioprinting have ushered in a new era of precision medicine by enabling the recreation of complex tumor microenvironments. This review highlights the transformative potential of 3D bioprinting technology in modelling prostate cancer stem cells (PCSCs) to identify therapeutic vulnerabilities and develop targeted treatments. By integrating bioinks with PCSCs and their niche components, 3D bioprinting offers a robust platform to investigate the molecular and cellular mechanisms underlying PCa progression and resistance. Furthermore, it allows high-throughput drug screening, cellular cross talks, facilitating the discovery of novel interventions aimed at eradicating CSCs while preserving healthy tissue. The review also discusses the challenges of scalability, bioink optimization, and clinical translation, alongside emerging technologies such as organ-on-chip systems and bioprinted metastatic models. This review underscores the promise of bioprinting as a disruptive innovation in cancer care, capable of redefining therapeutic approaches and offering hope for better patient outcomes in PCa.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107007"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nitidine chloride may mediate its antitumor effects by targeting kinesin family member 20A in colorectal cancer cells.","authors":"Ke-Jun Wu, Da-Tong Zeng, Rong-Quan He, Dong-Ming Li, Jin-Lian Yao, Li-Min Liu, Wei-Jian Huang, Di-Yuan Qin, Yu-Feng Li, Han He, Shi-De Li, Jia-Ying Wen, Li Meng, Jia-Rong Shi, Gang Chen, Hui Li","doi":"10.5306/wjco.v16.i7.108666","DOIUrl":"10.5306/wjco.v16.i7.108666","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of colorectal cancer (CRC) in younger people is increasing. Despite advances in precision medicine, the challenges of drug resistance and high costs persist. Nitidine chloride (NC) has pharmacological potential, and kinesin family member 20A (KIF20A) is overexpressed in various tumors; however, their interaction in CRC remains unexplored.</p><p><strong>Aim: </strong>To investigate the KIF20A expression characteristics in CRC cells and determine whether it is a potential target gene for NC in inhibiting CRC treatment.</p><p><strong>Methods: </strong>Single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and mRNA expression profiling were used to analyze KIF20A expression in CRC cells. Immunohistochemical staining was used to verify KIF20A expression in 416 clinical samples (208 CRC tissue samples and 208 noncancerous control tissue samples). Clustered regularly interspaced short palindromic repeats (CRISPR) technology was used to evaluate the impact of knocking out KIF20A on CRC cell growth. Molecular docking was applied to analyze NC-KIF20A binding. Finally, RNA sequencing and functional enrichment analysis were performed to explore the mechanism of action of NC in CRC cells.</p><p><strong>Results: </strong>Treating HCT116 cells with NC was found to significantly downregulate KIF20A (<i>P</i> < 0.05), and the molecular docking analysis revealed high-affinity binding between NC and KIF20A (binding energy = -9.6 kcal/mol). The scRNA-seq, spatial transcriptomics, and mRNA expression profiling results confirmed the significantly high expression of KIF20A in CRC tissues (standardized mean difference = 1.33, 95% confidence interval: 0.885-1.77, summary receiver operating characteristic curve area = 0.94). The immunohistochemical analysis of the clinical samples showed high KIF20A expression in the CRC tissues (<i>P</i> < 0.05), with significant correlation between the level of expression and gender, tumor size, and tumor grade (<i>P</i> < 0.05). Knocking out KIF20A significantly inhibited the growth of various CRC cell lines (CRISPR score < -0.3). The functional enrichment analysis indicated that NC may inhibit CRC by disrupting several biological processes, such as mitotic nuclear division, chromosome segregation, and microtubule binding.</p><p><strong>Conclusion: </strong>Our results indicate that NC binds to KIF20A with high affinity and downregulates its expression in CRC cells, leading to reduced proliferation. Hence, NC has promise as a therapeutic agent in the treatment of CRC, and targeting KIF20A also has potential as a therapeutic strategy. Further KIF20A knockout studies are needed to confirm the binding specificity and mechanistic roles of NC in CRC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108666"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological distress in thyroid cancer patients: Influencing factors and intervention strategies.","authors":"Ju-Hua Li, Qian Zhou","doi":"10.5306/wjco.v16.i7.106249","DOIUrl":"10.5306/wjco.v16.i7.106249","url":null,"abstract":"<p><p>Thyroid cancer is a common endocrine malignancy with a rising incidence. Patients often suffer from mental pain due to concerns about recurrence, treatment-related side-effect, and body image changes. Demographic factors like age, gender, physiological factors such as somatic symptoms and disease stage, cognitive-regulatory factors including negative and positive thinking, and social factors like work, economy, education level, and social support all influence their mental state. Existing interventions, including nursing, psychological, and traditional Chinese medicine-based methods, have some benefits but face limitations like short-term effectiveness and lack of standardization. Future research should focus on creating better-defined, long-term, and widely applicable intervention programs and explore positive psychology-based approaches to improve patients' mental well-being and quality of life.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"106249"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}